IMV Inc. (IMV) Reports Q2 Loss of $0.11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures outperform after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Dollar General stock jumps on earnings beat and raised guidance
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
August 11, 2021 7:05 AM EDTAppointed Andrew Hall, Chief Business Officer, as interim CEO, Jeremy Graff, PhD as Chief Scientific Officer, Stanley Frankel, MD and Jose Iglesias, MD as Clinical Advisors Strengthened financial position and extended cash runway with the completion of a $25M financing resulting in pro-forma cash and cash equivalents of $45.8 million on June 30th, 2021 Completed the DeCidE1 Phase 2 clinical study in advanced, recurrent ovarian cancer. Translational analyses confirm generation of tumor-antigen directed T cells by maveropepimut-S Initiated Phase 2B trial in... More
